Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Decernotinib

Home DrugsDecernotinib

Investigational

Small Molecule

Decernotinib

Unknown Manufacturer

Decernotinib has been used in trials studying the treatment of Drug Interactions and Rheumatoid Arthritis.

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

Decernotinib has been used in trials studying the treatment of Drug Interactions and Rheumatoid Arthritis.

Technical identifiers

Chemical Formula: C₁₈H₁₉F₃N₆O
CAS Number: 944842-54-0
UNII ID: MZK2GP0RHK

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Application of decenotinib in preparation of externally applied medicine for treating psoriasis, medicine and preparation method of medicine
CN 110403944 AApplicant: XIANGYA HOSPITAL CENTRAL SOUTH UNIVPriority: 2019
CN